ATE75940T1 - Verfahren zur herstellung eines arzneimittels auf fenofibrat-basis und dadurch erhaltenes arzneimittel. - Google Patents

Verfahren zur herstellung eines arzneimittels auf fenofibrat-basis und dadurch erhaltenes arzneimittel.

Info

Publication number
ATE75940T1
ATE75940T1 AT87401824T AT87401824T ATE75940T1 AT E75940 T1 ATE75940 T1 AT E75940T1 AT 87401824 T AT87401824 T AT 87401824T AT 87401824 T AT87401824 T AT 87401824T AT E75940 T1 ATE75940 T1 AT E75940T1
Authority
AT
Austria
Prior art keywords
fenofibrate
medication
manufacture
microns
medicine
Prior art date
Application number
AT87401824T
Other languages
English (en)
Inventor
Jean-Francois Boyer
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9338169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE75940(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Application granted granted Critical
Publication of ATE75940T1 publication Critical patent/ATE75940T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT87401824T 1986-08-08 1987-08-06 Verfahren zur herstellung eines arzneimittels auf fenofibrat-basis und dadurch erhaltenes arzneimittel. ATE75940T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8611540A FR2602423B1 (fr) 1986-08-08 1986-08-08 Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
EP87401824A EP0256933B1 (de) 1986-08-08 1987-08-06 Verfahren zur Herstellung eines Arzneimittels auf Fenofibrat-Basis und dadurch erhaltenes Arzneimittel

Publications (1)

Publication Number Publication Date
ATE75940T1 true ATE75940T1 (de) 1992-05-15

Family

ID=9338169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87401824T ATE75940T1 (de) 1986-08-08 1987-08-06 Verfahren zur herstellung eines arzneimittels auf fenofibrat-basis und dadurch erhaltenes arzneimittel.

Country Status (13)

Country Link
US (2) US4800079A (de)
EP (1) EP0256933B1 (de)
JP (1) JP2571693B2 (de)
AT (1) ATE75940T1 (de)
AU (1) AU601462B2 (de)
CA (1) CA1293194C (de)
DE (1) DE3779009D1 (de)
DK (1) DK175867B1 (de)
ES (1) ES2041699T3 (de)
FR (1) FR2602423B1 (de)
GR (1) GR3004698T3 (de)
NO (1) NO174876C (de)
ZA (1) ZA875758B (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
WO1996035516A1 (en) 1995-05-09 1996-11-14 Colorcon Limited Electrostatic coating
US7008668B2 (en) * 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
DE19608750A1 (de) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
GB9623634D0 (en) * 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU764001B2 (en) 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
CN1221249C (zh) * 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
SK288117B6 (sk) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6838091B2 (en) * 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6383517B1 (en) 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
GB0002305D0 (en) * 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
AU2001257115B2 (en) 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6531158B1 (en) 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1385548B1 (de) * 2001-01-26 2007-05-23 Schering Corporation Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
KR20070120617A (ko) * 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
PT1363668E (pt) * 2001-01-26 2007-11-07 Schering Corp Combinaçoes de sequestrante(s) de ácidos biliares e inibidor(es) de absorção de esterol e tratamento de indicações vasculares
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
WO2002096415A2 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (de) * 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
DE60229406D1 (de) * 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US7039078B2 (en) * 2002-09-17 2006-05-02 Nippon Telegraph And Telephone Corporation Semiconductor optical modulator and laser with optical modulator
CA2504916A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CN100367947C (zh) * 2002-12-04 2008-02-13 徐州恩华赛德药业有限责任公司 具有抗高血脂症的含非诺贝特的药物组合物
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1572190B1 (de) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
EP1832285A1 (de) * 2002-12-17 2007-09-12 Abbott GmbH & Co. KG Formulierung mit Fenofibrinsäure oder einem physiologisch verträglichen Salz davon
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
WO2004081002A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) * 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
GB2420298B (en) * 2003-06-18 2006-08-23 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
KR20060085686A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
GB0330171D0 (en) * 2003-12-30 2004-02-04 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
GB0407312D0 (en) * 2004-03-31 2004-05-05 Phoqus Pharmaceuticals Ltd Method and apparatus for the application of powder material to substrates
US20060177512A1 (en) * 2004-04-05 2006-08-10 Yihong Qiu Process for preparing formulations of lipid-regulating drugs
JPWO2006033435A1 (ja) * 2004-09-24 2008-05-15 株式会社ハイレックスコ−ポレ−ション 生体硬組織または軟組織誘導性スカフォールド材料
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
CN106075449A (zh) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
EP1785133A1 (de) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
RU2417100C2 (ru) * 2006-10-17 2011-04-27 Литера, Инк. Способы, композиции и препараты для лечения тиреоидной офтальмопатии
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
FR2940118B1 (fr) 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
KR101202994B1 (ko) 2010-04-12 2012-11-21 한미사이언스 주식회사 페노피브린산 및 알칼리화제를 포함하는 경구용 약학 조성물
BR112013012994A2 (pt) 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
EP2842547A1 (de) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Verbesserte Fenofibratzusammensetzungen
ES2830352T3 (es) * 2013-09-18 2021-06-03 Univ Georgetown Tratamiento de enfermedad neurodegenerativa con fenofibrato y análogos del mismo
EP2878311A1 (de) 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Verbesserung der Löslichkeit für hydrophobe Wirkstoffe
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296B1 (de) 2018-07-20 2026-04-01 Lipocine Inc. Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR14558E (fr) * 1911-07-05 1912-01-11 Henry Dreyfus Procédé pour la fabrication de nouveaux éthers de la cellulose et de leurs produits de transformation
US2154185A (en) * 1937-09-30 1939-04-11 Carborundum Co Bonded abrasive and method of making the same
DE1094929B (de) * 1956-04-19 1960-12-15 Pfizer & Co C Verfahren zum Dragieren von Zuckerkernen
US3143473A (en) * 1961-08-16 1964-08-04 Behringwerke Ag Stable, solid, oral live antipoliomyelitis vaccine compositions and process for preparing them
US3672945A (en) * 1968-10-18 1972-06-27 Fruitgrowers Chem Co Ltd Granules comprising inert cores coated with an absorbent powder
US4025613A (en) * 1971-07-19 1977-05-24 Richard G. Powers Timed-release aspirin
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
FR2236483B1 (de) * 1973-07-12 1976-11-12 Choay Sa
US4011061A (en) * 1975-03-20 1977-03-08 Minnesota Mining And Manufacturing Company Articles providing sustained release and method of making
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4259315A (en) * 1980-06-13 1981-03-31 A. H. Robins Company, Inc. Controlled release potassium dosage form
FR2494112B1 (de) * 1980-11-19 1986-01-10 Laruelle Claude
LU84526A1 (de) * 1982-12-10 1983-06-13 Distributa Sa Doxycyclinkapseln und verfahren zu deren herstellung
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
FR2554718B1 (fr) * 1983-11-14 1986-04-04 Ethypharm Sa Nouvelles formes galeniques du sulpiride utilisables par voie orale
JPH0830004B2 (ja) * 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
US4859703A (en) * 1987-06-15 1989-08-22 Warner-Lambert Company Lipid regulating compositions
US4837031A (en) * 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen

Also Published As

Publication number Publication date
FR2602423A1 (fr) 1988-02-12
DK411887D0 (da) 1987-08-07
JPS6348212A (ja) 1988-02-29
DE3779009D1 (de) 1992-06-17
NO174876B (no) 1994-04-18
EP0256933A1 (de) 1988-02-24
AU7660387A (en) 1988-02-11
DK411887A (da) 1988-02-09
ES2041699T3 (es) 1993-12-01
NO174876C (no) 1994-07-27
NO873320D0 (no) 1987-08-07
CA1293194C (en) 1991-12-17
US4800079A (en) 1989-01-24
US4961890A (en) 1990-10-09
NO873320L (no) 1988-02-09
EP0256933B1 (de) 1992-05-13
GR3004698T3 (de) 1993-04-28
DK175867B1 (da) 2005-04-18
JP2571693B2 (ja) 1997-01-16
ZA875758B (en) 1988-04-27
FR2602423B1 (fr) 1989-05-05
AU601462B2 (en) 1990-09-13

Similar Documents

Publication Publication Date Title
DE3779009D1 (de) Verfahren zur herstellung eines arzneimittels auf fenofibrat-basis und dadurch erhaltenes arzneimittel.
ATA290884A (de) Verfahren zur herstellung eines arzneimittelpraeparates mit kontrollierter und gleichmaessiger freigabe des arzneimittelwirkstoffes
DE3852299D1 (de) Verfahren zur herstellung magnetisch empfindlicher polymerteilchen und deren anwendung.
DE68928956D1 (de) Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
DE69218332D1 (de) Verfahren zur Herstellung von Zeichen, das eine durch Waschen entfernbare Antiklebschicht verwendet und Vorrichtung hierfür
DE68905205D1 (de) Verwendung von igf-i zur herstellung eines praeparats fuer die behandlung und die verhuetung von nebeneffekten von hyperinsulinemia bei diabetikern behandelt mit insulin.
DE3877751D1 (de) Kunstlunge vom membrantyp und verfahren zur herstellung.
ATA901482A (de) Material zur herstellung von artikeln zur abstuetzung des kopfes oder von gliedmassen des menschen oder von tieren, sowie aus diesem material hergestellte artikel
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
ATE87801T1 (de) Verfahren und vorrichtung zur herstellung von reissverschluessen.
DE59101776D1 (de) Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen.
DE3888892D1 (de) Verfahren zur Herstellung von supraleitenden Oxiden und dünne Schichten aus diesen Oxiden.
DE3787703D1 (de) Inklusionskomplex von Ibuproxam mit beta-Cyclodextrin, Verfahren zur Herstellung und diesen Inklusionskomplex enthaltendes pharmazeutisches Präparat.
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE68914927D1 (de) Halbleiteranordnung vom mit Plastik umhüllten Typ und Verfahren zur Herstellung derselben.
ATE76636T1 (de) Verfahren zur herstellung von benzoesaeure und ihren salzen.
EP0345247A3 (de) Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung
DE68915310D1 (de) Verfahren zur Herstellung von enantiomerischen homogenen Aminopyrrolidinyl-naphthyridin- und Quinoloncarbonsäuren.
DE68916683D1 (de) Transparenter doppelbrechender Film und Verfahren zur Herstellung desselben.
DE69029234D1 (de) Verfahren zur Herstellung von Dünnschichtsupraleitern und supraleitenden Einrichtungen
ATA903783A (de) Verfahren zur herstellung neuer 6-(1'-fluoraethyl) - und 6-(1'-fluor-1'-methylaethyl)-carbapeneme, von deren salzen, estern und geschuetzten formen
ATE136299T1 (de) Verfahren zur herstellung der racemischen und optisch aktiven 1,2,3,4-tetrahydroisochinolin-3- carbonsäure sowie deren vorprodukte
DE3773716D1 (de) Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.
AT375940B (de) Verfahren zur herstellung neuer 10-halogen-14-oxo-15-hydroxy-e-homoeburnane (3 alpha,17 alpha) sowie deren epimeren, optisch aktiven antipoden und physiologisch vertraeglichen saeureadditionssalze

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time